SureTrader SureTrader
Home > Boards > Other Markets > Foreign Stock Markets >

Pharming Group (PHARM)

PHARM RSS Feed
Add PHARM Price Alert      Hide Sticky   Hide Intro
Moderator: pedromm, yesmistermorningstar
Search This Board:
Last Post: 2/10/2016 7:05:42 AM - Followers: 4 - Board type: Free - Posts Today: 0

 

PHARMING GROUP

Market Euro-Nm
Symbol PHARM
ISIN number NL 0000377018
"Fondscode" 37701
Common code 15661178
Bloomberg symbol PHAR NA
Reuters symbol PHAR.AS
 

A/S 1.300.000.000

 O/S 06/07/2012  724,248,676

http://www.pharming.com/index.php

March 21, 2011
Santarus And Pharming Announce Rhucin Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting

Immunology 2011 Annual Meeting
- Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced new data on 62 patients with Hereditary Angioedema (HAE) who received repeat treatment with the investigational drug RHUCIN® (recombinant human C1 inhibitor) for 168 acute angioedema attacks. The median time to beginning of relief of symptoms across treatments for repeat attacks was approximately 60 minutes with response rates that were consistently 90% or greater. This open-label study was an extension of the randomized, double-blind, placebo-controlled study conducted by Pharming in North America. The findings were presented Sunday, March 20, 2011 in a poster session at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2011 Annual Meeting in San Francisco.

 

February 28, 2011
Santarus And Pharming Announce Receipt Of FDA Refusal To File Letter For Rhucin Biologics License Application

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced the receipt of a "refusal to file" letter from the U.S. Food and Drug Administration (FDA) for the RHUCIN® (recombinant human C1 inhibitor) Biologics License Application (BLA) submitted by Pharming. In the letter the FDA indicated that the BLA was not sufficiently complete to enable a critical medical review.
 

December 03, 2010
Pharming Announces Euro 16.1 Million Investment From Socius Capital Group
Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced the Company has entered into a definitive agreement with Socius CG II, Ltd, a subsidiary of Socius Capital Group, LLC ("Socius"), a Delaware limited liability company. Socius, based in New York and Los Angeles, has completed financings with numerous life sciences and other emerging growth companies in the United States and Europe. Pharming will receive €16.1 million gross proceeds in cash in return for non-convertible debt notes and equity if Socius exercises its investment rights.

October 28, 2010
Pharming's Ruconest™ For HAE Granted European Marketing Authorization
Biotech company Pharming Group NV (Pharming or "the Company") (NYSE Euronext: PHARM) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) today announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest™ for the treatment of acute attacks of Hereditary Angioedema (HAE). Pharming will now receive a €5 million milestone payment from marketing and distribution partner Sobi.

 

 

September 13, 2010
Pharming Signs Commercialization Agreement With Santarus For Rhucin® In North America
Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it has entered into an agreement with specialty biopharmaceutical company Santarus, Inc ("Santarus") (NASDAQ: SNTS) for the commercialization of Rhucin® (recombinant human C1 inhibitor; Ruconest™ in Europe) in North America (the United States, Canada and Mexico) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE) and other future indications

August 25, 2010
Pharming Plans Submission Rhucin BLA To Us FDA End 2010
Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it intends to submit the Biologic License Application (BLA) to the US Food and Drug Administration (FDA) to obtain marketing approval for Rhucin® for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE). Following pre-BLA discussions with the FDA, Pharming is preparing the BLA dossier for submission towards the end of this year but no later than January 2011.

 

in http://www.pharming.com/index.php?act=inv

 

Ruconest is a novel biotech alternative to plasma derived C1inh for the
treatment of HAE attacks
- Identical amino acid sequence
- Differences in glycosylation profile
- Highly purified
• Approved at a higher dose (50U/kg) achieving optimal efficacy
- Similar affinity to target proteases
- Functional units are directly comparable (1vial of Ruconest> 4 vials of plasma product)
- Dose is more important driver of efficacy than half-life
- No relapse
• Reassuring safety profile
- No pharmacological AEs
- No induction of allergies observed
- No induction of neutralizing antibodies
- Contraindicated in pts with rabbit allergy


 

The Rabbit in the Hat; Initiating Coverage with a Buy Rating
We are initiating coverage of Pharming with a Buy rating and a $0.35 price target. The key investment driver for Pharming is its innovative transgenic animal platform for production of complex recombinant proteins for therapeutic use. With an E.U.-approved product and late stage development in the U.S. and several international partners, Pharming represents a potentially significant value proposition, in our view.

 


 



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PHARM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#374   Expanding the around globe! Jimbers 02/10/16 07:05:42 AM
#373   Year results in about a month. Could get Jimbers 02/08/16 10:32:33 AM
#372   I could imagine Pharming Group starting to get Jimbers 02/08/16 10:27:34 AM
#371   tomorrow big day for pharming !!!!!!!!!!! plumo 10/27/15 09:38:24 AM
#370   Pharming Confirms Receipt Of US$20 Million Milestone Payment plumo 11/04/14 06:41:18 AM
#369   Salix & Pharming Announce the Launch of RUCONEST® plumo 11/03/14 03:42:18 AM
#368   LEIDEN (Reuters) - The Leiden biotechnology company Pharming biginvestors 08/24/14 05:25:36 AM
#367   FDA Approval Of RUCONEST For Acute Angioedema Attacks xr_biotech_consult 07/17/14 02:50:04 AM
#366   Hi alle, Check Pharming is growinggggggggggg strafpleiter 05/13/14 04:38:34 AM
#365   BLA xr_biotech_consult 02/18/14 12:02:03 PM
#364   So it was recently accepted by Israel ? yesmistermorningstar 02/17/14 03:09:34 PM
#363   Got it ! yesmistermorningstar 02/17/14 03:07:37 PM
#362   What is happening on April 16th ? yesmistermorningstar 02/17/14 03:03:05 PM
#361   how high will we go till 16.april :-) xr_biotech_consult 02/17/14 12:13:50 PM
#360   How high will we go today ? yesmistermorningstar 02/17/14 04:51:02 AM
#359   Pharming going strong 2-3 target. yesmistermorningstar 02/17/14 04:41:40 AM
#358   http://investorshub.advfn.com/boards/board.aspx?board_id=26028 xr_biotech_consult 01/23/14 09:20:16 AM
#357   about yes xr_biotech_consult 01/23/14 09:15:34 AM
#356   Hi Plumo, are you in ? yesmistermorningstar 01/20/14 10:32:20 AM
#355   Nice call ! yesmistermorningstar 01/20/14 10:31:09 AM
#354   Do you still have $2 as your target ? yesmistermorningstar 01/20/14 10:29:18 AM
#353   Stock of the future ? yesmistermorningstar 01/20/14 10:27:41 AM
#352   Wonder how far this will go ? yesmistermorningstar 01/20/14 10:27:21 AM
#351   Breaking out on news of license to sell. yesmistermorningstar 01/20/14 10:25:06 AM
#350   GOGO pharming GO Penger 01/17/14 05:30:41 AM
#349   We reiterate our Buy rating and $2.00 price target. xr_biotech_consult 04/25/13 01:38:49 PM
#348   PHGUF: BLA Filed For Ruconest, As Anticipated; Reiterate xr_biotech_consult 04/25/13 01:38:07 PM
#347   Santarus and Pharming Announce Submission of RUCONEST Biologics plumo 04/17/13 11:17:21 AM
#346   Directorate Change plumo 08/03/12 04:04:30 PM
#345   Pharming Announces Restructuring Plan plumo 08/02/12 05:42:45 AM
#344   Pharming Secures €10 Million Working Capital Facility From plumo 08/01/12 03:58:07 PM
#343   Pharming Confirms Safety Profile Of Recombinant Human Lactoferrin plumo 07/16/12 04:11:06 AM
#342   Pharming Updates On Shares In Issue plumo 07/06/12 03:22:46 AM
#341   Pharming Completes Recruitment Of Ruconest® US Pivotal Phase plumo 07/05/12 04:53:29 AM
#340   Pharming Announces Sale Of US Facilities plumo 07/03/12 03:21:39 AM
#339   Effects of C1 Inhibitor on Tissue Damage in plumo 07/02/12 02:12:48 AM
#338   New Data Published On Ruconest’s Protective Effects After plumo 07/02/12 02:10:37 AM
#337   Pharming Provides Management Update plumo 06/19/12 06:48:20 AM
#336   Pharming Announces Presentation Of New Ruconest® Clinical Data plumo 06/18/12 02:56:34 AM
#335   Pharming Updates On Study 1310 And Shares In plumo 06/15/12 03:21:29 AM
#334   bad news . plumo 06/12/12 09:16:54 AM
#333   Pharming Undertakes Review Of Strategic Options plumo 06/12/12 09:15:58 AM
#332   nice day today!!!!!!!! plumo 06/06/12 01:57:19 PM
#331   Pharming Reports Financial Results First Quarter 2012 plumo 04/26/12 01:08:59 AM
#330   Pharming Redeems Fourth Tranche Of Convertible Bond plumo 04/11/12 07:03:16 AM
#329   Pharming and Hyupjin Corporation announce commercialisation agreement for plumo 03/26/12 07:04:21 AM
#328   wsw.com/webcast/roth26/pharm/ plumo 03/14/12 04:17:39 AM
#327   Pharming Redeems Third Tranche Of Convertible Bond plumo 03/12/12 06:15:55 AM
#326   Pharming To Present At Roth Growth Conference On plumo 03/08/12 02:58:15 AM
#325   Pharming Announces Preliminary Financial Results 2011 plumo 03/01/12 01:13:19 AM
PostSubject